Raysearch Laboratories Ab Class B · OMXSTO:RAY_B
Raysearch Laboratories Ab Class B — Q3 2026 Earnings Presentation
20 slides from Raysearch Laboratories Ab Class B's earnings presentation, Nov 3, 2026
Slide 1: Interim Report Q3 2026
INTERIM REPORT Q32026 |NOVEMBER,32026
Slide 2: Agenda
AGENDA INTRODUCTION Q3 IN BRIEF FINANCIAL DEVELOPMENT SUMMARY AND OUTLOOK Q&A
Slide 3: Introduction
vi INTRODUCTION
Slide 4: RaySearch Today
RAYSEARCH TODAY 480 employees and41 nationalities 26 163 software industrial partners 11 MILLION cancer patients treated releases 10.3 billion SEK 13 sales offices and19 distributors in accumulated revenues 1,248 RayStation clinics in54 countries
Slide 5: Revenues – Solid Performance Over Time
REVENUES– SOLID PERFORMANCE OVER TIME 1400 1344 1332 Support revenue Licenses, hw, training, other 1192 1200 CAGR 19% 1022 1000 844 820 799 800 719 742 MSEK 652 641 606 627 585 600 532 521 398 544 408 373 400 512 285 518 204 485 524 533 182 356 416 473 200 118 126 84 256 269 323 63 159 179 198 244 3
Slide 6: Quarterly Fluctuations, Growth Every Year
QUARTERLY FLUCTUATIONS, GROWTH EVERY YEAR 600 1 344 1 332 1 400 1 192 1 200 500 1 022 1 000 400 844 742 800 300 627 652 641 585 532 600 200 398 400 285 182 204 100 118 126 200 63 84 0 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Net Sales (Quarterl
Slide 7: Q3 in Brief
vi 03 IN BRIE
Slide 8: Record-High Net Sales
RECORD-HIGH NET SALES 394 18% 35% 21% Net sales Organic Recurring EBIT MSEK growth support of total margin revenue
Slide 9: Q3 Business Update
Q3 BUSINESS UPDATE Strong net sales driven by USA Key orders Online adaptive collaboration with Accuray, including largeRayStationorder UNC School of Medicine in USAexpands RayStationuse Sylvester Comprehensive Cancer Center, Miami, choseRayStationto replace Eclipse for itsProBeamsystem Various phot
Slide 10: Other Q3 Highlights
OTHER Q3 HIGHLIGHTS Advanced Radiation Therapeutics started patient treatments using RayCare and RayStation with Varian TrueBeam Successful ASTRO congress in Boston Share buyback of 58 MSEK
Slide 11: IAEA's Rays of Hope Initiative
IAEA’S RAYS OF HOPE INITIATIVE Multi-year partnership with the International Atomic Energy Agency (IAEA) Expands access to cancer care in low - and middle-income countries Supports IAEA Anchor Centres– regional radiotherapycentresof expertise RaySearch contributes with software, training and technic
Slide 12: Financial Development
FINANCIAL D -FLOPM EN] RaySeqreh YO Laboratories
Slide 13: Order Intake
ORDER INTAKE License orders increased 65 percent 1 366 Order intakeincreasedby 30% 1 258 1 276 1 277 1 251 410 1 209 1 223 385 Strong contribution from Americas and 1 100 1 087 330 356 order from Accuray MSEK 295 296 305 253 241 Order backlog 1,722 MSEK end of Q3 Book-to-bill ratio of 1.0 Q3 Q4 Q1 Q
Slide 14: Net Sales and Operating Margin by Quarter
NET SALES AND OPERATING MARGIN BY QUARTER Record high net sales including high hardware volumes 394 Net sales grew19% to394 (332) MSEK 375 293 323 332 305 332 27% Organic growth 18% 24% 290 23% 23% 272 23% 21% 21% Temporary larger share of hardware MSEK impacted gross margin 84 (96)% 12% 10% EBIT of
Slide 15: Support Revenue Development
SUPPORT REVENUE DEVELOPMENT 40% recurring support revenue LTM 524 523 525 533 517 462 473 491 507 Support revenue of 138 (130) MSEK 51 90 Adjusted for currency +7%growth 17 31 41 40 43 42 Driven by high hardware sales, support MSEK 32 133 160 165 186 185 167 revenue accounted for 35% in Q3 131 125 1
Slide 16: Cash Flow Development
CASH FLOW DEVELOPMENT 198 177 Free cash flow of -68 (-82) MSEK 154 97 82 90 104 Effected byincrease in working capital 47 Profitable sales with longer payment MSEK 14 66 91 terms 24 30 50 1 7 -82 -68 Net cash position of 92 MSEK (excluding leasing) end of Q3 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Strong financi
Slide 17: Summary and Outlook
fv SUMMARY AND OUTLOOK RaySeqreh YO Laboratories
Slide 18: Summary and Outlook
SUMMARY AND OUTLOOK Strong net sales development and order momentum in USA Robust pipeline on growing proton market and increasing photon market share Further upselling potential within existing customer base Gradual expansion of offering beyond radiation therapy Strong Q4 expected and EBIT margin t
Slide 19: Q&A
Q&A
Slide 20: Thank You
THANK YOU Year-end reportreleased on Feb 10, 2027 If you have questions, please contact: ir@raysearchlabs.com
RaySearch Laboratories — Q3 2026 Earnings Presentation on 6ix